Again's $67 Million Funding History Versus Its Genomatica Acquisition Ambition

Again has raised $67 million since its founding in 2021, according to PitchBook. That is the funding base behind a company that just acquired Genomatica, a 28-year-old biotechnology firm with a far deeper capital history and a portfolio of more than 1,100 patents. The gap between those two numbers says something worth unpacking for anyone tracking the biomanufacturing supply landscape.

Again's own PyroCO2 project also carries a separate €43 million Horizon Europe grant, which some trackers fold into a broader "total raised" figure closer to $100 million. Either way, the comparison against Genomatica's capital history is stark.

Again's Funding Timeline So Far

Again's fundraising path has moved in a few distinct steps since the company launched out of research at the Technical University of Denmark.

• A $10 million seed round backed by ACME Capital, GV and Berlin-based Atlantic Labs, alongside a €43 million Horizon Europe grant for the PyroCO2 project.

• A $43 million Series A round in 2024 co-led by GV and HV Capital, with participation from Kompas VC, Denmark's Export and Investment Fund, ACME Capital and Atlantic Labs.

• A combined equity total that PitchBook puts at $66.7 million, spread across 13 investors including Denmark's Export and Investment Fund, DG Daiwa Ventures, HV Capital and GV.

That funding built a working pilot plant in Copenhagen and a commercial-scale Texas facility producing acetic acid from industrial CO2, plus an offtake agreement with global chemical distributor HELM AG. It is real infrastructure, but it is infrastructure built on a fraction of the capital that Genomatica accumulated over its lifetime.

Genomatica's Much Deeper Capital Base

Genomatica's funding history reflects a company that has been operating since 1998, nearly three decades longer than Again has existed at all.

Genomatica raised a total of $388 million across 13 funding rounds, backed by investors including Lululemon, Casdin Capital and Novo Holdings. That capital funded decades of fermentation process development, including commercial-scale technology now used to produce 1,4-butanediol from sugar, and built a patent portfolio of more than 1,100 filings covering pathway design and bioprocess engineering.

Put simply, Again spent roughly $67 million building toward this deal. Genomatica took nearly $400 million and 28 years to build the asset Again just acquired.

What Buying Scale Instead of Raising It Signals

The size mismatch is exactly why this deal is notable. Rather than spending years and hundreds of millions of dollars building comparable process knowledge, patents and commercial-scale credibility from scratch, Again is acquiring it directly.

A few things point to why this route made sense for a company at Again's funding stage:

• Genomatica's cofounder Christophe Schilling already sat on Again's board before the deal, suggesting the relationship and strategic fit were established well before any acquisition talks.

• Again has described the deal's core value as data, meaning two decades of experimental results and scale-up insights that would be extremely expensive to replicate independently.

• The acquisition gives Again a path into new renewable feedstocks, including sugars, without needing to fund that research internally over multiple years.

Buying maturity is often cheaper than building it, provided the acquiring company can actually finance the purchase. That is where the undisclosed terms become genuinely relevant rather than just a footnote.

Why the Financing Structure Matters to Buyers

With no disclosed purchase price, it is not possible to know whether Again paid largely in cash, equity, or some structured combination, and each of those routes has different implications for the combined company's near-term financial stability.

A company with $67 million in total funding acquiring one that raised nearly six times that amount is not necessarily a red flag. Deal structures involving equity swaps, earn-outs or investor-backed financing are common in exactly this kind of situation. But it does mean buyers sourcing from either company should not assume the acquisition was simply funded off Again's existing balance sheet.

What Chemical Buyers Should Watch For

For procurement teams and traders with a stake in either company's output, a few practical questions follow from this funding gap.

• Ask whether the deal introduced new investors or lenders to the combined company, since that can signal additional financial backing beyond what public funding totals show.

• Watch for a follow-on funding announcement. Companies that acquire assets larger than their existing capital base often need to raise again shortly after to support integration and working capital needs.

• Monitor production continuity at Genomatica's existing commercial partners, since integration costs and priorities can affect capacity allocation independent of the deal's financing structure.

• Track Again's Texas acetic acid facility output as a real-time signal of whether the company's core production is expanding or holding steady through the integration period.

None of these signals require the deal price itself. They are visible indicators buyers can track regardless of whether Again and Genomatica ever disclose a number.

The Bottom Line for Procurement Teams

Funding totals are a useful lens, but they only tell part of the story. Again's $67 million raised looks modest next to Genomatica's $388 million history, yet the acquisition still went through, which says as much about Genomatica's board-level ties to Again and the strategic value of its patent portfolio as it does about capital alone.

For buyers, the smarter move is tracking operational signals like production continuity, follow-on funding and leadership retention rather than waiting on a valuation that may never be disclosed. The funding gap is real, but it does not automatically predict how the combined company performs from here.